Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.36 |
| ▸ | CASP6 | P55212 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27832464 | 0.88 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL380654 | 0.85 | HDAC1 (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL10306807 | 0.84 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1644146 | 0.84 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL27853917 | 0.84 | PSEN1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2556806 | 0.77 | ADRB2 (0.39) | HDAC1HDAC6HDAC5KAT6ACASP6 | |
| SCHEMBL375075 | 0.76 | MPO (0.46) | CASP6MPO | |
| SCHEMBL27832466 | 0.76 | KAT6A (0.35) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL23166186 | 0.76 | BACE1 (0.40) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL310646 | 0.76 | NISCH (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408756-B1 | ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2408450-B1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL MYERS SQUIBB CO (US) | 2013-03-13 | — | — | EP | disclosed |
| US-8350084-B2 | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8350084-B2 | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| US-8350084-B2 | Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2295417-B1 | Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound | BRISTOL MYERS SQUIBB CO (US) | 2012-07-04 | — | — | EP | disclosed |
| EP-2471769-A1 | Process for preparing a benzonitrile derivative | Bristol-Myers Squibb Company (US) | 2012-07-04 | — | — | EP | disclosed |
| CN-102438622-A | A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production | BRISTOL MYERS SQUIBB CO | 2012-05-02 | — | — | CN | disclosed |
| US-20120088925-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-12 | — | — | US | disclosed |
| US-20120088925-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-12 | — | — | US | disclosed |
| WO-2010108067-A1 | ALPHA-(N-BENZENESULFONAMIDO)CYCLOALKYL DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | disclosed |
| EP-2205575-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | Bristol-Myers Squibb Company (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY | 2009-09-10 | — | — | US | disclosed |
| WO-2009058552-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009058552-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090111858-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-30 | — | — | US | disclosed |
| US-20090111858-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-30 | — | — | US | disclosed |
| US-20090111858-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | BRISTOL-MYERS SQUIBB COMPANY | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111858-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | APP, BACE1, IAPP | PSEN1 5/4885PSEN2 8/4885APH1B 9/4885 |
| US-20120088925-A1 | Novel Alpha-(N-Sulfonamido)Acetamide Compound as an Inhibitor of Beta Amyloid Peptide Production | APP, BACE1, IAPP | PSEN1 5/4885PSEN2 8/4885APH1B 9/4885 |
| US-20090227642-A1 | NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | APP, BACE1, APBA1 | PSEN1 4/4885PSEN2 9/4885APH1B 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.